Location Directory

Clinical trials in Jacksonville, Florida

This page shows live ClinicalTrials.gov search results for Jacksonville, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 8:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

7622

Shown on this page

Current sort

Institutions in Jacksonville

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Mayo Clinic

Live official records

Open in full search

Conditions: Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
Interventions: Biospecimen Collection, Cabozantinib, Computed Tomography, Everolimus, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Sunitinib; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 35
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more

Conditions: Recurrent Pericarditis, Heart Diseases, Pericarditis
Interventions: KPL-387; Drug
Lead sponsor: Kiniksa Pharmaceuticals International, plc; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 21
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 17 more

Conditions: Non-squamous Non-small Cell Lung Cancer
Interventions: Rilvegostomig, Pembrolizumab, Carboplatin, Cisplatin, Pemetrexed; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 78
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 72 more

Conditions: Nonalcoholic Steatohepatitis
Interventions: AZD2693, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 36
States / cities: Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 32 more

Conditions: Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Interventions: Vicadrostat, Empagliflozin, Placebo matching Vicadrostat; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 11,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 208
States / cities: Anniston, Alabama • Fairhope, Alabama • Guntersville, Alabama + 171 more

Conditions: Major Depressive Disorder (MDD)
Interventions: SPN-821 2400 mg, Placebo; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 40
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 34 more

Conditions: Healthy
Interventions: Wellness Check and Socialization, Prepared Meals; Behavioral · Other
Lead sponsor: Brown University; Other
Eligibility: 66 Years and older
Enrollment: 2,300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 14
States / cities: San Diego, California • Clearwater, Florida • Jacksonville, Florida + 11 more

Conditions: Extrapulmonary Neuroendocrine Cancer (epNEC)
Interventions: Obrixtamig, Carboplatin, Etoposide, Ventana DLL3 RxDx assay; Drug · Device
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 21
States / cities: Scottsdale, Arizona • Duarte, California • San Francisco, California + 17 more

Conditions: Malignant Glioma
Interventions: Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor; Procedure · Radiation · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Months to 21 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 111
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more

Conditions: Advanced Solid Tumor
Interventions: Lunresertib, RP-3500, Zedoresertib; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 12 Years and older
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 12 more

Conditions: Hypertension, Hypercortisolemia, Cushing Syndrome
Interventions: Osilodrostat, Placebo; Drug
Lead sponsor: RECORDATI GROUP; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Jacksonville, Florida • Canton, Ohio • Weslaco, Texas

Conditions: Advanced or Metastatic Non-small Cell Lung Cancer
Interventions: Rilvegostomig, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab-paclitaxel, Ramucirumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: Phoenix, Arizona • Santa Rosa, California • Jacksonville, Florida + 6 more

Clinical trials in Jacksonville, Florida

Filter and sort this location

Institutions in Jacksonville

Live official records

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Transition to KPL-387 Monotherapy Dosing & Administration Study

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

Deliver-EE: Evaluating Effects of Meal Delivery

DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors

Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)